 Lysis plasminogen activator-resistant platelet-rich coronary artery thrombus combined bolus injection recombinant tissue-type plasminogen activator antiplatelet GPIIb/IIIa antibody Resistance coronary occlusive thrombus thrombolytic therapy patients acute myocardial infarction due presence platelet-rich coronary clot Reperfusion therapy patients development evaluation alternative strategies animal models platelet-rich coronary artery thrombus excision eversion reanastomosis cm segment left circumflex coronary artery anesthetized dogs heparin antiocoagulation Blood flow dogs Thrombotic occlusion everted segment graft platelet-rich thrombus thrombus platelet-rich erythrocyte-rich zones min min mean SD dogs dogs group control stable occlusion ultrasound flow probe coronary angiography observation period group II intravenous bolus injections recombinant tissue-type plasminogen activator rt-PA dose mg/kg body min intervals reperfusion dogs cyclic reperfusion reocclusion dog group III single intravenous bolus injection mg/kg fragment murine monoclonal antibody human platelet GPIIb/IIIa receptor stable reperfusion dogs whereas occlusion group IV injection mg/kg rt-PA mg/kg stable reperfusion reocclusion dogs versus rt-PA alone versus control study platelet-rich occlusive coronary thrombus resistant intravenous rt-PA resistance use dose rt-PA antiplatelet GPIIb/IIIa receptor antibody results platelet-rich thrombus resistant thrombolytic agents resort mechanical recanalization present dog model useful specific strategies dispersion resistant platelet-rich coronary thrombus